Navigation Links
Schering-Plough Selects Benefit Advocates for Health Advocacy
Date:1/15/2009

WINSTON-SALEM, N.C., Jan. 15 /PRNewswire/ -- Benefit Advocates Inc. will help 18,500 employees and retirees of Schering-Plough Corporation resolve claims, billing and other health insurance issues.

President and CEO Mary L. Kesel said that Schering-Plough contracted with her firm to provide advocacy services for its United States-based employees and retirees and their families beginning Jan. 1, 2009.

Headquartered in Winston-Salem, N.C., and founded in 2001, Benefit Advocates provides health advocacy services to individuals and large and small businesses nationwide including SCANA Corporation, SunTrust Banks, Inc., Deere-Hitachi Construction Machinery Corporation and Denny's Corporation.

"We're pleased to welcome Schering-Plough into our growing family of client companies," Kesel said. "Our experienced benefit advocates now look forward to helping Schering-Plough employees and retirees save time and money by negotiating on their behalf with health insurers, hospitals, doctors and other providers.

"When they call, they will get our 'Real People, Real Answers' service -- not a phone menu -- that we believe is so key to our growth and the high satisfaction with our services."

Schering-Plough (NYSE: SGP) is a global science-based health care company offering prescription, animal health and consumer health care products. Headquartered in Kenilworth, N.J., the company has 55,000 employees worldwide and operates in more than 140 countries. With $12.7 billion in net 2007 sales, the company's leading products are Vytorin, Zetia, Remicade and Nasonex.

    Media Contact:
    Mary Kesel
    President and CEO
    Benefit Advocates
    www.benefitadvocates.net
    336-721-2029


'/>"/>
SOURCE Benefit Advocates Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
2. Schering-Plough Schedules Conference Call and Webcast for 2007 Third Quarter Earnings
3. Schering-Plough Reports Financial Results for Third Quarter of 2007
4. Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment
5. Schering-Plough Reports U.S. District Court for District of Massachusetts Finds No Liability for Subsidiary in AWP Case
6. Schering-Plough to Webcast CFO Robert J. Bertolinis Presentation at 2007 Credit Suisse Health Care Conference
7. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
8. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
9. Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
10. Schering-Plough Board Elects Dr. Craig B. Thompson as a Director
11. Schering-Plough CEO to Buy $2 Million in Common Shares

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...ociation of Urology (EAU) and Europa Uomo, the Eur...state cancer, have entered into an,affiliated par...increase and improve,patient awareness in Europe ...Per-Anders Abrahamsson, Secretary-General of the E...ship, Europa Uomo will gain access to the latest i...
(Date:11/30/2009)...gs of gravy and dessert at the holiday table are e...ly thought. According to a new research report rec...tp://www.fasebj.org ), a diet that is high in fat ...ately cause our bodies to store too much fat. This... the already difficult task of converting high-fat...
(Date:11/30/2009)...SHENZHEN, China, Nov. 30 /PRNewswire-FirstCall/ - ...ical.com/ ) operating subsidiary Mellow Hope final...facturer of intravenous medication in India. This ...for Hard to Treat Diseases in the following quarte... company secures the supply of raw pharmaceutical ...
(Date:11/30/2009)...OLIS, Nov. 30 A new study has foun...Medicare insurance customers have a current intent... coverage. The figure is up from 20% in 2008. Ov...measure has been a leading indicator of actual swi...tention to switch actually will leave their curren...
(Date:11/30/2009)... and Senate bills stack up , , MONDAY, N...ills moving through the U.S. Congress differ in a ...ic reduction in the number of uninsured Americans....ntatives earlier this month would expand coverage ...g to debate a proposal to expand coverage to 94 pe...
Breaking Medicine News(10 mins):Health News:Western diets turn on fat genes 2Health News:Hard to Treat Diseases (HTDS) Closes 1 Million Dollar Contract Indian Pharmaceutical 2Health News:Hard to Treat Diseases (HTDS) Closes 1 Million Dollar Contract Indian Pharmaceutical 3Health News:More Seniors Considering Health Insurance Switch 2Health News:Health Reform: What's in It for You? 2Health News:Health Reform: What's in It for You? 3
...ent of coronary artery diseases, in which a thin p...ains the medicine// which can prevent scar formati...the stent without surgery introduces drug. Sir...g blood clots in the arteries without surgical met...
...e grapefruit is a thing to cheer for people suffer...t people with gum disease who ate two grapefruits ...eeding from the gums. The study was performed ...an increase in blood levels of vitamin C, known to...
...d that cold and flu drugs containing pseudoephedri... in an effort to limit illegal manufacturing of su...effect from January 1 in Queensland. Pharmacists h...often used as a raw material to manufacture speed ...
...ts from tissue that may have been illegally harves... positive for hepatitis // and syphilis, their la...re Memorial Hospital in Somers Point, N.J., and cl...ases within the last two weeks. The lawyer, And...
...tsunami waves had left over 25,000 people dead and...Indian Ocean countries. // One in five Thai tsun...year's disaster that forever changed the physical,...nami survivors are still suffering the post trauma...
...hat can detect the Hepatitis C virus using saliva ...i of Soroka University Medical Centre // in Israe... people without kidney functions whose blood must ... The researchers reported 100 percent success...
Other Medicine News:
(Date:11/30/2009)..., WALTHAM, Mass., Nov. 30 Decis... and advisory firms focusing on pharmaceutical and... virus drug market in Russia will grow nine percen...hing $327 million by 2013. This growth will be dri...lthcare and increased use of more-expensive therap...
(Date:11/30/2009)... , INDIANAPOLIS, Nov. 30 /PRNewswire-FirstCall...as approved Cymbalta® (duloxetine HCl) for th...order (GAD) in adults, Eli Lilly and Company (NYSE...d anxiety disorder can be a chronic illness, it is...treatment option that is effective in both the acu...
(Date:11/30/2009)..., BRIDGEWATER, N.J., Nov. 30 /PRNewswire-FirstCall...ng of an exclusive licensing agreement with Intell...for the emergency treatment of allergic reactions ... ,, "We are pleased to have this opportunity to...lions of people who are at risk of this life-threa...
Breaking Medicine Technology:Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 2Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 3FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 2FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 3FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 4FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder 5Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America 2Sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America 3China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 1China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 2China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 3China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 4China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 5China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 6China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 7China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 8China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 9China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 10China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 11China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 12China Medical Technologies Reports FY2009 First Fiscal Quarter Unaudited Financial Results 55810 13Head of Process Sciences at aTyr Pharma to Speak at Bio Korea 2009 4928 1Head of Process Sciences at aTyr Pharma to Speak at Bio Korea 2009 4928 2MarketsandMarkets 3A Global Autoimmune Treatment Market Worth US 2468 81 Billion by 2014 13750 1MarketsandMarkets 3A Global Autoimmune Treatment Market Worth US 2468 81 Billion by 2014 13750 2MarketsandMarkets 3A Global Autoimmune Treatment Market Worth US 2468 81 Billion by 2014 13750 3MarketsandMarkets 3A Global Autoimmune Treatment Market Worth US 2468 81 Billion by 2014 13750 4
... American Association for Cancer Research,annual m...ire-FirstCall/ --,Medarex, Inc. today presented pr...tivity from two separate studies exploring the,eff... anti-CD70,antibody-drug conjugates. CD19 and CD70...conjugate approach to cancer therapy. They are,exp...
...the American Association for Cancer Research,(AACR...- Lorus,Therapeutics Inc. ("Lorus") today announce... and siRNA compounds at the 98th,Annual Meeting of... The first presentation titled, "Determination of ...docetaxel combination,treatment for NSCLC cells in...
Other Medicine Technology:Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 2Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 3Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor,Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in,Cancer Animal Models 4Lorus Therapeutics Announces Scientific Presentations for Lead,Antisense and siRNA Drug Candidates at International Cancer,Conference 2Lorus Therapeutics Announces Scientific Presentations for Lead,Antisense and siRNA Drug Candidates at International Cancer,Conference 3Lorus Therapeutics Announces Scientific Presentations for Lead,Antisense and siRNA Drug Candidates at International Cancer,Conference 4Lorus Therapeutics Announces Scientific Presentations for Lead,Antisense and siRNA Drug Candidates at International Cancer,Conference 5
Revo Rotator Cuff Repair System
BioROC EZ Fasteners and Instrumentation
...a fully absorbable soft tissue anchor designed spe...s dynamic engagement into cancellous bone, its bro...de significant resistance to pullout in soft bone....ction provides the benefits of fixation strength c...
...ade; Ti Quick-T Fixation System is a single-step t...r secondary tissue fixation. This through tendon t...e Anchor combined with our pretied knot technology...e of PEEK-OPTIMA® LT3 polymer from Invibio. Th...
Medicine Products: